MYL : Analysis & Opinions

  1. The Drug Price-Fixing Probe Is Just the Beginning

    December 19, 2016
    Federal prosecutors are charging several generic drug makers with price-fixing.
  2. Mylan's Herceptin Copycat Progresses (MYL, RHHBY)

    November 10, 2016
    Mylan is closing in on a copycat to rival Roche’s blockbuster Herceptin drug.
  3. Mylan's Price Hike: EpiPen Suit May Go Nationwide

    October 18, 2016
    A woman whos EpiPen bill rose twelvefold in a year filed a class action suit against Mylan last month. If the class is certified, ...
  4. Pharma Stocks Prone to Decline From Democratic Win (MYL, ARIA)

    October 17, 2016
    Amid the political bashing of price raises by drug manufacturers, here are the stocks most prone to declines.
  5. Mylan Settles EpiPen Overcharging Suit for $465M

    October 10, 2016
    On Friday, pharmaceuticals maker Mylan NV (NASDAQ: MYL) agreed to pay $465 million to the Justice Department to settle claims ...
  6. Mylan Reaches $465M EpiPen Settlement (MYL)

    October 10, 2016
    After being accused of price gauging by the U.S. government, Mylan, the makers of EpiPen, agreed to a $465 million settlement; ...
  7. Investors Find More Reasons to Dump Mylan Stock

    October 3, 2016
    Shares of EpiPen maker Mylan (NASDAQ: MYL) are down over 30% year-to-date amid media and regulatory scrutiny, and consumer ...
  8. 5 of the Stock Market's Biggest Losers This Year (SCTY, MYL)

    September 29, 2016
    Both the S&P 500 and the Dow Jones have hit record highs this year and the Fed announced it will keep interest rates unchanged. ...
  9. Revisiting Three Market Villains (CMG, VRX)

    September 27, 2016
    Mylan, Chipotle, and Valeant Pharmaceuticals CEOs have learned that traders have the final word when executives fail to address ...
  10. 5 of the Worst-Performing Industries in 2016 (MYL, UAL)

    September 19, 2016
    The S&P 500 has tallied a 5.05% YTD increase - but if you take a closer look, you’ll see that some industries are lagging ...
  11. Mylan’s Sneaky EpiPen Maneuvers

    September 17, 2016
    Drugmaker Mylan has become a target of criticism in response to claims that it’s engaging in sneaky EpiPen maneuvers to shield ...
  12. Is Mylan The Next Valeant Trade? (MYL, VRX)

    September 2, 2016
    Mylan is caught in a political firestorm after EpiPen price increases while short sellers drool over a possible Valeant Pharmaceuticals ...
  13. Mylan to Offer Cheaper, Generic Version of EpiPen

    August 29, 2016
    Faced with a rising storm of public and political outrage, pharmaceutical company Mylan (NASDAQ: MYL) said it will launch ...
  14. Mylan to Launch a Cheaper Generic EpiPen (MYL)

    August 29, 2016
    To address the uproar over EpiPen's higher price, Mylan will be launching a cheaper generic alternative.
  15. Mylan Enhances Access to EpiPen After 545% Price Hike (MYL)

    August 25, 2016
    Mylan has promised to take measures to ease the financial burden of its life-saving medicine.
  16. Top 5 Health Care Stocks of 2016 (AMGN, BMY)

    August 25, 2016
    Discover why the baby boomers are benefiting the health care sector. Explore five health care stocks that are well positioned ...
  17. Two Senators Investigate Pricing of Mylan's EpiPen (MYL)

    August 23, 2016
    Mylan is coming under attack by two U.S. Senators who are demanding to know why the price of the EpiPen allergy drug has ...
  18. Pfizer Exits Brazil: Teva Is Suitor (PFE, TEVA)

    July 29, 2016
    Pfizer is planning to exit the Brazilian market as it puts its generic drug joint venture stake up for sale. Teva and Mylan ...
  19. Look to Buy These Broken Wedge Patterns (CNI, MYL)

    July 25, 2016
    These stocks are breaking out of downward wedge formations, or close to it, which indicates the stock price could be heading ...
  20. Is Einhorn Investing in the Next Valeant Stock? (VRX)

    June 29, 2016
    Learn why famed hedge fund manager David Einhorn initiated a long position in Mylan despite regulatory concerns about the ...
  21. Why Lannett Cut Its Guidance for Fiscal 2016

    March 24, 2016
    Lannett (NYSE: LCI) has revised downward its guidance for the current fiscal year. Among other line item projections, the ...
  22. Momenta, Mylan Collaboration on Biosimilars Looks Solid for Both ...

    January 11, 2016
    Momenta Pharmaceuticals Inc and Mylan Inc announced a world-wide collaboration on six biosimilar mAbs.
  23. The Top 5 Large-Cap Healthcare Stocks for 2016 (GILD, ANTM)

    January 6, 2016
    Learn about the potential direction for large-cap stocks in the health care sector in 2016, drug pricing headwinds and the ...
  24. Perrigo Urges Shareholders to Reject New Mylan Bid

    September 18, 2015
    A takeover battle waged by a pair of generic drugs producers is heating up. On Thursday, the management of acquisition target ...
  25. Why We Need Antitrust Laws (MSFT, AAPL)

    July 29, 2015
    A look at antitrust laws in the United States and the many anticompetitive practices they safeguard against.
  26. Teva Pharma to Acquire Allergan: Analysts Weigh In

    July 28, 2015
    Teva Pharmaceutical announced a definitive agreement to buy Allergan Inc. for $40.5 billion. What analysts are saying?
  27. The Pharmaceutical Feud: Mylan, Teva and Perrigo

    June 3, 2015
    Find out what Tipranks' analysts think about several pharmaceutical giants competing in the realm of mergers and acquisitions.
  28. Are These 2015's 10 Best Generic Pharma Stocks?

    June 3, 2015
    These 10 generic generic pharma stocks present a lot of upside potential for the second half of 2015. Here's why.
  29. How to Profit from the Generic Drug Trend

    June 3, 2015
    Generic drugs are poised to steal market share as patent protections on a number of branded drugs expire. Investors should ...
  30. What To Do With Stocks That Hit All-Time Highs

    May 13, 2015
    Apply this specialized set of risk management and technical rules when your positions are trading at new highs.
  31. How Bristol-Myers Squibb Makes the World Healthier

    April 10, 2015
    Innovation and acquisition: an in depth look at pharma giant Bristol-Myers Squibb.
  32. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...